Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4293441 | 0.80 | MAPK1 (0.47) | MAPK1KMT2AMGLLNR1H2ACHE | |
| SCHEMBL3396724 | 0.77 | NR1H2 (0.60) | MAPK1KMT2ANR1H2ACHELMNA | |
| SCHEMBL31202932 | 0.77 | NR1H2 (0.50) | MAPK1KMT2ANR1H2ACHELMNA | |
| SCHEMBL21280252 | 0.75 | KMT2A (0.50) | MAPK1KMT2ANR1H2ACHELMNA | |
| SCHEMBL3401846 | 0.74 | KMT2A (0.44) | MAPK1KMT2AMGLLNR1H2ACHE | |
| SCHEMBL3399817 | 0.73 | CYP2A13 (0.61) | MAPK1KMT2AACHELMNA | |
| SCHEMBL29182981 | 0.72 | ACHE (0.63) | MAPK1KMT2ANR1H2ACHECYP2D6 | |
| SCHEMBL3396475 | 0.72 | KMT2A (0.45) | MAPK1KMT2ANR1H2ACHELMNA | |
| SCHEMBL4283821 | 0.72 | KMT2A (0.42) | MAPK1KMT2ANR1H2ACHECYP3A4 | |
| SCHEMBL3401722 | 0.72 | MAPK1 (0.40) | MAPK1KMT2AMGLLNR1H2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| EP-2247591-A1 | PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | MAPK1 13/4885KMT2A 1885/4885MGLL 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.